Table 3.

Multivariate analysis of composite outcome in patients with AAV

	P value	Hazard ratio	95 % confidence interval
Model A
Age	0.69	0.99	0.96–1.02
Gender (male vs. female)	0.32	1.44	0.71–2.91
Hemoglobin (≤9 g/dl vs. >9 g/dl)	0.31	1.47	0.70–3.11
Urinary protein (per g/24 hour)	0.02	1.29	1.05–1.58
Plasma CFH levels (per 50 μg/ml increase)	0.03	0.85	0.73–0.98
Model B
Age	0.72	0.99	0.96–1.03
Gender (male vs. female)	0.36	1.39	0.69–2.82
Total crescents (%) (>50 % vs. ≤50 %)	0.26	1.69	0.68–4.17
Urinary protein (per g/24 hour)	0.09	1.21	0.97–1.52
Plasma CFH levels (per 50 μg/ml increase)	0.03	0.85	0.73–0.98
Model C
Age	0.31	1.02	0.99–1.05
Gender (male vs. female)	0.75	1.12	0.55–2.29
Initial serum creatinine (per mg/dl)	<0.001	1.24	1.12–1.36
Urinary protein (per g/24 hour)	0.002	1.34	1.12–1.62
Plasma CFH levels (per 50 μg/ml increase)	0.57	0.96	0.83–1.11

AAV, anti-neutrophil cytoplasmic antibody-associated vasculitis, CFH complement factor H